Analysts name Boston Scientific among other companies as ripe for acquisition
This article was originally published in Clinica
Boston Scientific is one of the most likely targets for acquisition by another company this year, according to one industry analyst. In his Medical Products 1999 Outlook report dated December 31, Hambrecht & Quist's senior analyst, Robert Faulkner, wrote that the company was one of the most likely targets for acquisition or merger, possibly by Johnson & Johnson.
You may also be interested in...
Advanced Medical Solutions said it will buy Raleigh Adhesive Coatings for £22m ($29m) in cash to strengthen its overall wound care business.
While Amgen said the Phase III GALACTIC-HF results for omecamtiv mecarbil did not meet its high expectations for the heart failure candidate, Cytokinetics sees a path to treating certain patients.
Lilly has launched a similar antibody product, but demand is expected to outpace supply for the foreseeable future.